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A B S T R A C T
Background
The role of postoperative radiotherapy (PORT) in the treatment of patients with completely resected non-small cell lung cancer
(NSCLC) was not clear. A systematic review and individual participant data meta-analysis was undertaken to evaluate available evidence
from randomised controlled trials (RCTs). These results were first published in Lung Cancer in 2013.
Objectives
To evaluate the effects of PORT on survival and recurrence in patients with completely resected NSCLC. To investigate whether
predefined patient subgroups benefit more or less from PORT.
Search methods
We supplemented MEDLINE and CANCERLIT searches (1965 to 8 July 2016) with information from trial registers, handsearching
of relevant meeting proceedings and discussion with trialists and organisations.
Selection criteria
We included trials of surgery versus surgery plus radiotherapy, provided they randomised participants with NSCLC using a method
that precluded prior knowledge of treatment assignment.
Data collection and analysis
We carried out a quantitative meta-analysis using updated information from individual participants from all randomised trials. We
sought data on all participants from those responsible for the trial. We obtained updated individual participant data (IPD) on survival
and date of last follow-up, as well as details on treatment allocation, date of randomisation, age, sex, histological cell type, stage,
nodal status and performance status. To avoid potential bias, we requested information on all randomised participants, including those
excluded from investigators’ original analyses. We conducted all analyses on intention-to-treat on the endpoint of survival.
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Main results
We identified 14 trials evaluating surgery versus surgery plus radiotherapy. Individual participant data were available for 11 of these
trials, and our analyses are based on 2343 participants (1511 deaths). Results show a significant adverse effect of PORT on survival,
with a hazard ratio of 1.18, or an 18% relative increase in risk of death. This is equivalent to an absolute detriment of 5% at two years
(95% confidence interval (CI) 2% to 9%), reducing overall survival from 58% to 53%. Subgroup analyses showed no differences in
effects of PORT by any participant subgroup covariate.
We did not undertake analysis of the effects of PORT on quality of life and adverse events. Investigators did not routinely collect quality
of life information during these trials, and it was unlikely that any benefit of PORT would offset the observed survival disadvantage.
We considered risk of bias in the included trials to be low.
Authors’ conclusions
Results from 11 trials and 2343 participants show that PORT is detrimental to those with completely resected non-small cell lung
cancer and should not be used in the routine treatment of such patients. Results of ongoing RCTs will clarify the effects of modern
radiotherapy in patients with N2 tumours.
P L A I N L A N G U A G E S U M M A R Y
Postoperative radiotherapy for non-small cell lung cancer
Review question
Do patients with non-small cell lung cancer live longer if they are given radiotherapy after surgery?
Background
Non-small cell lung cancer is the most common type of lung cancer. If the tumour is early stage, is not too big and has not spread
to other parts of the body, doctors usually operate to remove it. Radiotherapy (treatment with x-rays) is sometimes given after the
operation, aiming to kill any remaining cancer cells.
In 1998, we did a systematic review and meta-analysis of individual participant data looking at trials of this treatment - postoperative
radiotherapy (PORT). This review brought together information from all patients who took part in similar trials. These trials compared
what happened to people with non-small cell lung cancer who were given radiotherapy after surgery and those who had surgery without
radiotherapy. Results were first published in The Lancet in 1998.
Since this review was completed, many trials have been done. To ensure that available evidence is as up-to-date as possible, we carried
out a new systematic review and meta-analysis of individual participant data that included all trials, old and new. As for the 1998
review, this review aimed to find out if giving radiotherapy after surgery (1) helps patients live longer, (2) stops cancer from coming
back (recurrence) and (3) stops cancer from spreading to other parts of the body (metastases).
These updated results were first published in Lung Cancer in 2013.
Study characteristics
We searched for relevant trials up to 8 July 2016. These studies brought together available trial data from all over the world, with 11
trials and 2343 patients. Trials were carried out between 1966 and 1998.
Key results
Results showed that fewer people given PORT treatment lived for two years after the operation (53 out of every 100 patients) than
those not given PORT after the operation (58 out of every 100 patients). Researchers reported no difference in effects of PORT by
types of patients included in trials.
Researchers did not routinely collect quality of life information during the trials, and it was unlikely that any benefit of PORT would
offset the observed survival disadvantage.
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Radiotherapy given after successful removal of tumour at operation is not beneficial for patients with non-small cell lung cancer and
should not be used as routine treatment; however, further research into new types of radiotherapy for patients at higher risk of recurrence
is ongoing.
Quality of evidence
These systematic reviews and meta-analyses use individual participant data, which are considered the gold standard for this type of
review. We included all eligible trials, if possible, no matter what language they were published in, or whether or not they were published.
This meta-analysis included 88% of all participants in eligible trials.
Studies were well designed and conducted and addressed the review question, with consistent effects noted across trials. The impact of
any data not included in our analyses is small.
B A C K G R O U N D
Description of the condition
Worldwide, carcinoma of the lung is the main cause of cancer
death. More than 1.5 million new cases are diagnosed each year
(Jemal 2011), about 85%ofwhich involve non-small cell lung can-
cer (American Cancer Society 2007). Surgery is the treatment of
choice for early non-small cell lung cancer (NSCLC) (NSCLCCG
1995), but only about 20% of tumours are suitable for potentially
curative surgery (Datta 2003). Even for patients with apparently
completely resected disease, survival is only around 40% at five
years. In an effort to improve local-regional control of the disease
and to increase survival, investigators have explored adjuvant post-
operative radiotherapy (PORT) as a therapeutic option.
Description of the intervention
This review concentrated on randomised controlled trials (RCTs)
that tested surgery alone comparedwith surgery followed by radio-
therapy. Radiotherapy in these trials was given by cobalt therapy,
by cobalt therapy and linear accelerators or by linear accelerators
only.
How the intervention might work
Radiotherapy may be given after surgery with the aim of killing
any remaining cancer cells.
Why it is important to do this review
Despite the conduct of several RCTs (most in the 1980s and
1990s) that recruited a total of more than 2000 patients, the role
of PORT in the treatment of patients with NSCLC has remained
unclear. Individually, trials showed inconclusive and conflicting
results. However, because of their size (74 to 539 participants), in-
dividual trials did not have sufficient statistical power to detect the
moderate survival differences that might be expected with PORT.
We therefore initiated an individual participant data meta-analysis
to assess this question. This approach to meta-analysis and sys-
tematic review involves the central collection, validation and anal-
ysis of original trial data. It does not rely on data extracted from
publications. At the outset, the project management group con-
tacted the investigators responsible for each trial and established
the PORT Meta-analysis Trialists Group, under whose auspices
the meta-analysis was conducted and published. This review was
first published in The Lancet in 1998 (PORT 1998). In 2005, the
meta-analysis was updated (PORT 2005) with data from one new
trial (Italy 2002). In 2009, the meta-analysis was updated again to
include data from another new trial (Korea 2007). However, since
this review was last updated, new methods developed to assess
treatment by patient covariates that are methodologically more
appropriate and less prone to bias have prompted this latest update
of the Cochrane review (Fisher 2011). Furthermore, changes over
time to the tumour-node-metastasis (TNM) staging system have
been taken into account in this update, and although the data did
not permit use of the seventh TNM edition, they did allow us
to convert tumour stage from the fourth (Mountain 1987) to the
fifth/sixth (Mountain 1997) edition.
O B J E C T I V E S
To evaluate effects of PORT on survival and recurrence in patients
with completely resected NSCLC. To investigate whether prede-
fined patient subgroups benefit more or less from PORT.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
To be included, both published and unpublished completed trials
had to be properly randomised using established methods (not
quasi-randomised). Trials could not have been confounded by ad-
ditional therapeutic differences between the two arms and must
have commenced randomisation on or after 1 January 1965. Tri-
als should have aimed to randomise participants with completely
resected non-small cell lung cancer between radiotherapy and no
immediate further treatment. Trials should not have used ortho-
voltage radiotherapy.
Types of participants
Eligible trials included individuals with histologically confirmed
NSCLC who had undergone a potentially curative resection. We
included in the meta-analyses individual participant data from
all randomised participants and, when possible, obtained data for
individuals who had been excluded from the original trial analyses.
We excluded from the meta-analyses, participants with small cell
lung cancer, who were included in early trials that randomised all
types of lung cancer.
Types of interventions
• Surgery versus surgery + postoperative radiotherapy
(PORT).
Types of outcome measures
• Survival.
• Recurrence-free survival.
• Local recurrence-free survival.
• Distant recurrence-free survival.
Primary outcomes
The primary outcome of overall survival was defined as the time
from randomisation until death by any cause. Living participants
were censored on the date of last follow-up.
Secondary outcomes
Recurrence-free survival was defined as the time from randomi-
sation until first recurrence, or death by any cause. Participants
alive without disease were censored on the date of last follow-up.
To avoid bias from under-reporting of subsequent events, time to
local-regional recurrence was defined as the time from randomi-
sation until first local-regional recurrence, with participants expe-
riencing earlier distant recurrences censored at the time of distant
recurrence. Similarly, for time to distant recurrence, participants
experiencing earlier local-regional recurrences were censored on
that date. Participants who died without recurrence were censored
on the date of death. Data on quality of life were not routinely
collected in these trials; therefore we could not analyse the data in
this review.
Search methods for identification of studies
To limit publication bias, we included published and unpub-
lished trials with no restrictions based on language. We carried
out searches of MEDLINE (Appendix 1) and CANCERLIT
from 1965 (using The Cochrane Collaboration’s optimal strategy
(Lefebvre 2001; Lefebvre 2008). We supplemented searches of
trial registers by conducting handsearches of conference proceed-
ings and reference lists of trial publications and review articles.
We asked our collaborators if they knew of additional trials. We
carried out the most recent searches in July 2016.
In 1997, we identified trials by electronic searches of MEDLINE
and CANCERLIT, using a modified version of the optimal search
strategy of The Cochrane Collaboration (Dickersin 1995), sup-
plemented by handsearches of Proceedings of the American Soci-
ety of Clinical Oncology (ASCO) (1990 to 2016) and the World
Conference on Lung Cancer (1990 to 2015) and bibliographies of
books, reviews and specialist journals. We also searched trial regis-
ters (CochraneCentral Register ofControlledTrials (CENTRAL),
theNational Cancer Institute Physicians DataQueryClinical Pro-
tocols andUnitedKingdomCo-ordinatingCommittee for Cancer
Research)and asked all trialists who took part in the meta-analysis
to help to identify additional trials. We regularly updated searches
to identify new trials and to assess the status of any ongoing trials.
Search updates in October 2002 and August 2003 identified one
new eligible trial (Italy 2002), and the search update carried out
in 2009 identified two new eligible trials: a Polish trial (Dymek
2003) and a Korean trial published as an abstract (Korea 2007).
We last carried out searches in July 2016 and identified no new
eligible trials.
Electronic searches
WemodifiedTheCochraneCollaboration’s optimum search strat-
egy for retrieving RCTs fromMEDLINE (Appendix 1) to specifi-
cally retrieve RCTs of radiotherapy for NSCLC, and we used this
search strategy to search MEDLINE and CANCERLIT (1965 to
2016).
In addition, we searched the following electronic bibliographic
databases.
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (1995 to 8 July 2016) (Appendix 2).
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• Proceedings of annual meetings of the American Society for
Clinical Oncology (ASCO) (1995 to 2016).
We used the following trial registers to supplement searches of
electronic databases with trials that were not (yet) published or
were still recruiting patients.
• United Kingdom Coordinating Committee on Cancer
Research (UKCCCR) Trials Register.
• ClinicalTrials.gov.
• Physicians Data Query Protocols (open and closed).
• Current Controlled Trials ‘metaRegister’ of controlled trials.
Searching other resources
Handsearches
We carried out the following handsearches to identify trials that
may have been reported only as abstracts, or that might have been
missed in the searches described above.
• Proceedings of the American Society for Clinical Oncology
(ASCO), 1990 to 1994.
• Proceedings of the International Association for the Study
of Lung Cancer (IASLC) World Lung Cancer Conference 1990
to 2015.
Searches of reference lists
We searched the bibliographies of all identified trials and review
articles.
Correspondence
We asked all participating trialists to review and supplement a
provisional list of trials.
Data collection and analysis
Selection of studies
Two members of the Project Management Group (SB, LR)
checked all titles and abstracts identified by electronic search-
ing and handsearching of conference proceedings, and obtained
full publications for those thought to be potentially relevant. We
sought individual participant data (IPD) from trial authors, in-
cluding updated follow-up, when available.
Data extraction and management
We sought IPD for all eligible trials, as well as updated information
on survival, recurrence and date of last follow-up, and details of
treatment allocated, date of randomisation, age, sex, histological
cell type, stage and performance status.
We used standard checks to identifymissing data.We verified data,
for example, by checking the order of the dates of randomisation,
and assessed data validity and consistency. To assess randomisation
integrity, we checked patterns of treatment allocation and balance
of baseline characteristics by treatment arm. We checked follow-
up of surviving participants to ensure that it was balanced by
treatment arm and up-to-date. We resolved queries, and each trial
investigator or statistician verified the final database.
As stage was recorded using different classification systems, for
the purposes of this meta-analysis we translated all stage data to a
common staging system,which has beenupdated since the original
analysis to reflect the TNM sixth edition classification (Table 1;
Table 2).
Assessment of risk of bias in included studies
We assessed included studies using the risk of bias tool of The
Cochrane Collaboration, as outlined in Table 8.5c of theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
two authors (SB, LR) checked these studies. We considered ade-
quate sequence generation and allocation concealment to be most
important; therefore a judgement of low riskwas desirable for these
domains for all trials. Blinding was not appropriate owing to the
nature of the treatments, and any issues surrounding reporting of
incomplete outcome data, selective outcome reporting or attrition
bias were overcome by collection of IPD.
Measures of treatment effect
Unless otherwise stated, we prespecified all analyses in the proto-
cols and carried out an intention-to-treat analysis. For each out-
come, we used the log-rank expected number of events and vari-
ance to calculate individual trial hazard ratios (HRs), which we
pooled across trials using the fixed-effect model (Yusuf 1985).
We presented overall survival using simple (non-stratified) Ka-
plan-Meier curves (Kaplan 1958) and computed median follow-
up for all participants by using the reverse Kaplan-Meier method
(Schemper 1996).
We analysed ’raw’ IPD using in-house software (SCHARP), then
entered the log-rank summary statistics of these analyses (O-E and
variance) into RevMan (RevMan 2014). We presented results as
absolute differences at five years, calculated with the HR and base-
line event rate on the surgery alone arm; we assumed proportional
hazards (Parmar 1995). We similarly calculated confidence inter-
vals for absolute differences from the baseline event rate and the
HR at 95% confidence interval boundary values.
To explore any impact of trial characteristics on effects of adjuvant
chemotherapy on overall survival, we calculated pooled HRs for
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each prespecified trial group and used Chi2 tests for interaction to
investigate differences in treatment effect across trial groups.
Dealing with missing data
Weoutlined all desired variables in a protocol (available on request)
and requested missing variables from those who carried out the
trials.
Assessment of heterogeneity
We used Chi2 tests and the I2 statistic (Higgins 2002) to test for
differences in treatment effect across groups of trials or groups of
participants.
Assessment of reporting biases
As we collected IPD, we encountered no reporting biases.
Data synthesis
When we could get data, we included all eligible trials in the
analyses. We carried out these analyses in SCHARP (in-house
software), Stata (Stata 2013) and RevMan (RevMan 2014).
Subgroup analysis and investigation of heterogeneity
To investigate differences in treatment effect across participant
subgroups, we undertook Cox regressions, including the relevant
treatment by subgroup interaction term within each trial. We
pooled these interaction coefficients (HRs) across trials (Fisher
2011) and investigated whether differences in treatment effect
could be identified that varied with participant age, sex, histolog-
ical cell type, tumour stage or performance status.
Sensitivity analysis
We outlined in the protocol that HRs for overall survival would
be calculated, excluding any trials that were clear outliers.
R E S U L T S
Description of studies
We identified 14 eligible trials (one unpublished) and included 11
trials in the review (see Characteristics of included studies). We
could not include three trials: Data for two trials were unavailable
(Dymek 2003 (150 participants); LCSG 841 (five participants)),
and it was unclear whether one study of 155 participants, which
was reported as a randomised controlled trial (RCT), was indeed
randomised. We were unable to obtain appropriate data for this
trial (Austria 1996) (see Characteristics of excluded studies).
Therefore, this update is based on the results of 11 RCTs (Belgium
1966; CAMS 1981; EORTC 08861; GETCB 04CB86; GETCB
05CB88; Italy 2002; Korea 2007; LCSG 773; Lille 1985; MRC
LU11; Slovenia 1988) and 2343 individuals. Across these trials,
PORT doses ranged from 30 Gy to 60 Gy, given in between
10 and 30 fractions, and considerable diversity was evident in
other aspects of radiotherapy planning. All trials included partici-
pants with completely resected tumours for which the disease stage
was no greater than IIIA. Most trials provided updated follow-
up giving a median of 4.4 years for surviving participants (2.3 to
11.4 years for individual trials). Baseline participant characteristics
show that most participants were male with stage II/III squamous
cell carcinoma (although histology was unknown for a relatively
large number of participants) with good performance status (Table
3).
Risk of bias in included studies
We included only trials with adequate methods of randomisation.
We excluded trials that used quasi-random methods, such as birth
date. We thoroughly checked all raw data received on individ-
ual participants to ensure both the accuracy of the meta-analysis
database and the quality of randomisation and follow-up. We re-
solved all queries and verified final database entries through dis-
cussion with the responsible trial investigator or statistician. No
RCTs were blinded owing to the nature of the intervention, but
the primary outcome is not likely to be influenced by lack of blind-
ing. For two trials, allocation concealment was unclear - one trial
was unpublished (EORTC 08861), and one was published only
as an abstract (Korea 2007) - but checks on IPD and correspon-
dence with those who supplied the data reassured us that the data
had been adequate. We received IPD for all outcomes of interest;
therefore we considered reporting bias to be low for all RCTs. We
considered all included trials to be at low risk of bias (see Figure 1
and Figure 2).
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Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Effects of interventions
Results were based on information from 11 RCTs (2343 par-
ticipants), representing 88% of individuals from all eligible ran-
domised trials. We collected data for 140 out of 142 participants
who had been excluded from the original published trial analy-
ses and were reinstated in this meta-analysis. For one trial, which
randomised all histological types of lung cancer (Belgium 1966),
we excluded the 20 participants with small cell tumours from
the meta-analysis. Survival and recurrence data were available for
all trials. All trials provided information on age, sex and stage,
and nine trials provided data on histology (Belgium 1966; CAMS
1981; EORTC 08861; Italy 2002; Korea 2007; LCSG 773; Lille
1985; MRC LU11; Slovenia 1988). Performance status data were
available for only four trials (EORTC 08861; Italy 2002; MRC
LU11; Slovenia 1988) andwere insufficient for assessment of treat-
ment by covariate interactions. All but two trials provided cause
of death data (coded as NSCLC, treatment-related or other) (Italy
2002; LCSG 773), although the trialists themselves questioned
the reliability of this information for many trials.
Survival
Survival data were available for all trials and included information
from 2343 participants and 1511 deaths (777 PORT, 734 surgery
alone). Although the confidence intervals (CIs) for individual trial
results were wide, combined results showed a significant adverse
effect of PORT on survival (P = 0.001), with a hazard ratio (HR)
of 1.18 (95% CI 1.07 to 1.31) (Analysis 1.1), or an 18% relative
increase in risk of death. This was equivalent to an absolute detri-
ment of 5% at two years (95% CI 2% to 9%), reducing overall
survival from 58% to 53%. Survival curves (Figure 3) appeared to
diverge at around fourmonths and remained apart for the five years
to which they could be drawn with reasonable reliability. There
was some evidence of increased statistical heterogeneity between
trials in the current update (I2 = 40%, P = 0.08), compared with
the original 1998 meta-analysis. However, the random-effects re-
sult is similar (HR 1.17, 95% CI 1.02 to 1.34, P = 0.02), and het-
erogeneity appears largely driven by the Italian trial (Italy 2002).
A sensitivity analysis excluding this trial reduces heterogeneity (I2
= 31%, P = 0.16) and gives similar fixed-effect (HR 1.20, 95% CI
1.08 to 1.33, P = 0.0005) and random-effects results (HR 1.20,
95% CI 1.06 to 1.37, P = 0.005).
Figure 3. Overall survival.
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Cause of death information coded asNSCLC, treatment related or
other was available for nine trials. Of 595 coded deaths on PORT,
82% were attributed to NSCLC, 4% to treatment-related causes
and 14% to other causes. For the 565 coded deaths on surgery
alone, these figures are 89%, 2% and 9%, respectively.
Local recurrence-free survival
Data on local-regional recurrence were available from all trials.
Analysis of local-regional recurrence-free survival, based on 1556
events (498 local-regional recurrences (200 on PORT, 298 on
surgery alone) and 1058 deaths (593 on PORT, 465 on surgery
alone)), gave a HR of 1.12 (95% CI 1.01 to 1.24), significantly
in favour of surgery alone (P = 0.03) (Analysis 1.2). There was
evidence of statistical heterogeneity between trials (I2 = 47%, P
= 0.04), which was not apparent in the 1998 analysis (I2 = 29%,
P = 0.19), and for this outcome, the random-effects result is less
convincing (HR 1.10, 95% CI 0.95 to 1.27, P = 0.19) than the
fixed-effect result. However, exclusion of the Italian trial (Italy
2002) again reduces heterogeneity to non-significant levels (I2 =
22%, P = 0.23), as well as giving similar fixed-effect (HR 1.15,
95% CI 1.04 to 1.27, P = 0.008) and random-effects estimates
(HR 1.15, 95% CI 1.02 to 1.29, P = 0.02). Results may suggest
an increase in local-regional recurrence on the PORT arm, but
the number of local-regional recurrences alone shows less local-
regional recurrence on the PORT arm and more events when
deaths without local-regional recurrence are included.
Distant recurrence-free survival
All trials provided data on distant recurrence. Analysis of distant
recurrence-free survival based on 1570 events (892 distant recur-
rences (438 on PORT, 454 on surgery alone) and 678 deaths (361
on PORT, 317 on surgery alone)) gave an HR of 1.13 (95% CI
1.02 to 1.24) in favour of surgery alone (P = 0.02) (Analysis 1.3).
There was no evidence of gross statistical heterogeneity between
trials (I2 = 31%, P = 0.15).
Overall recurrence-free survival
A total of 1597 events were observed, 810 on PORT and 787 on
surgery alone. Of these, 445 first events were deaths, 260 partic-
ipants had local-regional recurrences and 654 had distant recur-
rences (238 participants had both local-regional and distant re-
currences, of which 110 were recorded on the same date). The
overall HR of 1.10 (95% CI 0.99 to 1.21) potentially suggests
an adverse effect of PORT (P = 0.07) (Analysis 1.4). This 10%
relative increase in risk of recurrence or death was equivalent to an
absolute detriment of 3% at two years (95%CI 0% to 7%), reduc-
ing the recurrence-free survival rate from 48% to 45%. As with
local-regional recurrence-free survival, there was some evidence of
increased statistical heterogeneity between trials (I2 = 44%, P =
0.06) that was not present in the 1998 analysis (I2 = 26%, P =
0.21), and a random-effects analysis produces a less convincing
result (HR 1.09, 95% CI 0.95 to 1.25, P = 0.23). However, a
sensitivity analysis excluding the Italian trial (Italy 2002) not only
reduces heterogeneity (I2 = 20%, P = 0.26) but also gives similar
fixed-effect (HR 1.13, 95% CI 1.02 to 1.24, P = 0.02) and ran-
dom-effects (HR 1.13, 95% CI 1.00 to 1.26, P = 0.04) results.
Analyses by trial characteristics
Weplanned analysis for overall survival by trial characteristic based
on the planned energy beam delivery method (cobalt only, cobalt
and linac, linac only) and radiotherapy dose (< 45 Gy, ≥ 45 Gy).
We found no difference in effects of treatment on overall survival
depending on delivery method (P = 0.18) (Analysis 1.5). We did
find a difference by dose of radiotherapy (P = 0.02) (Analysis 1.6),
but 80% of data is in the >=45 Gy group, and the result in the <
45 Gy group subgroup alone is not significant.
Analyses by participant covariates
Based on data from all trials, for survival there was no evidence to
suggest that PORTwas differentially effective by age (interaction P
= 0.67), sex (P = 0.49) or histology (P = 0.38). For analysis by stage,
we could not include three trials because all participants were in a
single stage category (Italy 2002, Lille 1985 stage I only; Slovenia
1988 stage III only). Data from the remaining eight trials provide
no evidence to suggest that PORT was differentially effective by
stage within individual trials (Figure 4), but the meta-analysis of
these interactions suggests that PORTmay be most detrimental in
earlier-stage patients, although the result was not significant (HR
= 0.87, 95% CI 0.72 to 1.04, P = 0.12) (Figure 5). Similar results
were observed whether or not trials included all three stages or
only stage II and III participants (Figure 6; Figure 7). Exploratory
analyses of how the effect of PORT on local-regional, distant and
overall recurrence-free survival varies by stage gave similar results.
For analysis by nodal status, we could not include four trials be-
cause all participants were in a single subgroup category with N0
(Belgium 1966; Italy 2002; Lille 1985) or N2/3 (Slovenia 1988)
disease. Data from the remaining seven trials provided no evidence
to suggest that PORT was differentially effective by nodal status
within individual trials (Figure 8), nor in a meta-analysis of these
interactions (HR = 0.92, 95% CI 0.76 to 1.11, P = 0.39) (Figure
3).
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Figure 4. PORT effect on overall survival by trial according to stage.
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Figure 5. Hazard ratio (HR) for the interaction between the effect of PORT on survival and (a) stage or (b)
nodal status.
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Figure 6. Sensitivity analysis 1: only trials with all stage subgroups included.
13Postoperative radiotherapy for non-small cell lung cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 7. Sensitivity analysis (2): only trials with stage II and III subgroups represented.
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Figure 8. PORT effect on overall survival by trial according to nodal status.
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Results for stage andnodal status are different frompreviously pub-
lished results (PORT 1998; PORT 2005) largely for two reasons.
Here, we have used a method (Fisher 2011) to examine whether
the effect of PORT varied by participant covariates that was differ-
ent from the method used in the original review in 1998 (PORT
1998), and in the previous updates in 2005 and 2009 (PORT
2005). This new method is more appropriate and is less prone
to bias. We could not calculate several covariate interactions for
trials contributing participants in only a single covariate category;
therefore we did not include these studies; this approach, although
correct, can provide less power than the methods used previously.
Trials not included here also happen to have quite extreme results
and have had undue influence on previous analyses.
In this update, we wanted to take account of changes to the TNM
staging system; although the data do not allowus to use the seventh
edition, they do allow us to convert stage from the fourth to the
sixth edition; the major impact of this is that patients previously
classified as T3N0M0 (stage IIIA) have been reclassified as stage
IIB. This change affected 98 participants and Table 4 shows results
for stage and nodal status according to the combination of changes
made.
D I S C U S S I O N
At the outset of this project, despite enrolment of more than 2000
participants in randomised trials, it remained unclear whether
postoperative radiotherapy (PORT)was effective for the treatment
of patients with non-small cell lung cancer (NSCLC). The origi-
nal 1998 meta-analysis found a significant adverse effect of PORT
on survival (P = 0.001) with a hazard ratio (HR) of 1.21 (95%
confidence interval (CI) 1.08 to 1.34), or a 21% relative increase
in risk of death. We undertook this systematic review and indi-
vidual participant data meta-analysis to produce a comprehensive,
reliable and up-to-date summary of the average effect of PORT
in patients with NSCLC, to provide reliable guidance for clinical
practice and future research. Therefore, when a new trial of 111
participants was published (Korea 2007), we included this study
in an update of the analyses.
Overall, for the primary endpoint of survival, there was clear evi-
dence of a detrimental effect of PORT for patients with completely
resected NSCLC. The 18% relative increase in risk of death asso-
ciated with PORT, equivalent to an overall reduction in survival
from 58% to 53% at five years, represents a considerable hazard
for these patients. In contrast to the original meta-analysis and
previous updates, this update, using new and more appropriate
methods, did not provide evidence that the relative effect of PORT
was smaller or larger for patients of any category defined by age,
sex or histology. For analysis by stage, PORT tended to be most
detrimental in patients with earlier-stage disease, but this result
was not significant once 98 patients had been reclassified accord-
ing to the updated TNM system. Likewise, analysis by nodal sta-
tus shows a much less convincing relationship between the effect
of PORT and nodal status. Also, in the case of both stage and
nodal status analyses, trials with participants in only a single stage
or nodal status category (Lille 1985; Italy 2002; Slovenia 1988)
had a major impact on the original analyses, and so their appro-
priate exclusion from these analyses is significant. However, this
means that despite inclusion of more trials overall, less data were
included in this compared with the original analyses so power is
more limited.
All analyses of local-regional (P = 0.02), distant (P = 0.02) and
overall (P =0.08) recurrence-free survival (i.e. time to recurrence or
death) have suggested an overall adverse effect of PORT. However,
the observed detriment was less for these endpoints than for overall
survival. For local-regional recurrence-free survival, results were
driven largely by survival (as deaths account for the majority of
events). This suggests that antitumour activity may be attributable
to radiotherapy, and that increased risk of death from PORT may
be attributable to other mechanisms. Analysis of the local-regional
recurrence-free interval (i.e. the time to local-regional recurrence
with death and distant recurrence censored) was not presented
because such analysis would be difficult to interpret and would be
potentially seriously flawed. This difficulty arose because increased
risk of death with PORT may mean that patients treated with
PORT die before their tumour has had time to recur locally. Thus,
such measurement was likely to be an overestimation of local-
regional control.
Inclusion of the most recent trial (Korea 2007) has brought the
total number of participants to 2343 across 11 randomised con-
trolled trials (RCTs). As would be expected, the addition of this
modestly sized trial has not substantially changed the overall effect
of PORT on survival. As evidence from new trials has accumu-
lated, there has been some increase in heterogeneity, particularly in
relation to the Italian trial (Italy 2002), which, it should be noted,
included only participants with stage I disease.
However, a significant detriment of PORT for survival persists,
with similar estimates, irrespective of whether a fixed-effect or a
random-effects model is used. Results for local-regional and over-
all recurrence-free survival are less convincing. Furthermore, al-
though trials have been conducted over a period of 40 years, with
changes in diagnosis and assessment of recurrence and radiother-
apy, no clear evidence indicates that the effect of PORT has im-
proved over the decades.
In particular, much discussion over the past few years has focused
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on modern radiotherapy techniques such as those used in some
of the trials included here; the suggestion is that modern radio-
therapy (delivered by linear accelerator) may be less detrimental
than older methods (delivered by cobalt machines). Recent liter-
ature-based meta-analyses (Billiet 2014) could not confirm this,
providing a reported risk ratio (RR) for overall survival of 0.85
(95% confidence interval (CI) 0.59 to 1.22, P = 0.38) for trials
that used only linear accelerators. Indeed when we ran this same
analysis using our individual participant data, for those trials that
used only linear accelerators (albeit on a different selection of tri-
als), we observed a hazard ratio (HR) for overall survival of 1.02
(95% CI 0.80 to 1.31, P = 0.85; Analysis 1.5). Another recent
literature-based meta-analysis (Patel 2014) has suggested benefit
of PORT for overall survival when radiotherapy has been given
only with linear accelerators (HR = 0.77, 95% CI 0.62 to 0.92, P
= 0.02); however, this review used a combination of three RCTs
(some of which included chemotherapy) and eight retrospective
studies. Results of an ongoing trial may clarify this matter (Lung
ART-IGR 2006/1202).
Although this meta-analysis did not directly address quality of life
(none of the trials collected data on patient-reported quality of
life measures), it was unlikely that any benefits of PORT would
offset the observed survival disadvantage. Indeed the additional
time spent undergoing treatment and the side effects of radiation
could reasonably be expected to impair at least short-term quality
of life.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Although the radiotherapy used in most of the included trials is
now considered suboptimal, this update still provides the best ev-
idence that postoperative radiotherapy (PORT) has an adverse ef-
fect on survival. There is now less compelling evidence that the
effect of PORT varies by stage, and in particular nodal status, but
PORT should not be used routinely unless supporting evidence
can be obtained from an ongoing trial of modern PORT tech-
niques (Lung ART-IGR 2006/1202).
Implications for research
This meta-analysis has shown a clear adverse effect of postopera-
tive radiotherapy on survival. However, whilst PORT still tends
to be detrimental in early-stage disease, the result is no longer
significant. Researchers must evaluate PORT using modern ra-
diotherapy techniques. One recent systematic review (Patel 2014)
has suggested a benefit of PORT when radiotherapy is given only
with the use of linear accelerators; this review used a combination
of randomised controlled trials (RCTs) (some of which included
chemotherapy) and retrospective studies. Another recent review
(Billiet 2014) could not confirm benefit. A trial including partic-
ipants with N2 disease is currently ongoing (NCT00410683). If
further trials are initiated, accurate and detailed information on
the cause of death will be important, as will data regarding surgical
resection and radiotherapy technique. Collection of such data may
help to clarify whether a combination of radiation with surgery
or radiation alone is the cause of excess deaths with postoperative
radiotherapy.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Belgium 1966
Methods 1966 to 1977
RCT
Participants 224 patients
Stages I, II, III
Trial data used in subgroup analyses for sex, age and histology
Interventions Surgery + radiotherapy vs surgery alone
RT details
60 Gy in 30 fractions in 6 weeks
Prescription technique: isodose 90%
Machine used: Co60
Average field size (cm): 15 × 9
Clinical target volume: bronchial stump, hilum, mediastinum
Technique: spinal cord blocks, oblique fields, lateral fields
Outcomes Survival
Notes 20 small cell participants excluded from meta-analysis
Unable to supply data for 2 participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: stated as randomised in paper; checks run on IPD
suggest adequate sequence generation
Allocation concealment (selection bias) Low risk Quote: “randomisation carried out via sealed envelope”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: trial not blinded owing to the nature of the inter-
vention; outcome not likely to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: individual participant data obtained and checked for
all outcomes
Selective reporting (reporting bias) Low risk Comment: individual participant data obtained and checked for
all outcomes
Other bias Low risk Comment: study apparently free of other sources of bias
20Postoperative radiotherapy for non-small cell lung cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
CAMS 1981
Methods 1981 to 1995
RCT
Participants 317 patients
Stages II, III
Trial data used in subgroup analyses for sex, age, histology, stage and nodal status
Interventions Surgery + radiotherapy vs surgery alone
RT details
60 Gy in 30 fractions in 6 weeks
Prescription technique: at midplane
Machine used: Co60 and linac
Average field size (cm): 6 × 12
Clinical target volume: hilum, mediastinum
Technique: spinal cord blocks, oblique fields, lateral fields
Outcomes Survival
Notes Abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: stated as randomised in paper; checks run on IPD
suggest adequate sequence generation
Allocation concealment (selection bias) Low risk Quote: “randomisation carried out via sealed envelope”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: trial not blinded owing to the nature of the inter-
vention; outcome not likely influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: individual participant data obtained and checked for
all outcomes
Selective reporting (reporting bias) Low risk Comment: individual participant data obtained and checked for
all outcomes
Other bias Low risk Comment: study apparently free of other sources of bias
EORTC 08861
Methods 1986 to 1990 RCT
Participants 106 patients
Stages II, III
Trial data used in subgroup analyses for sex, age, histology, stage and nodal status
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EORTC 08861 (Continued)
Interventions Surgery + radiotherapy vs surgery alone
RT details
56 Gy in 28 fractions in 5.5 weeks
Prescription technique: central axis, at the midplane
Machine used: linac
Average field size (cm): 15 × 10
Clinical target volume: hilum, mediastinum
Technique: composite plans
Outcomes Survival
Notes Unpublished trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: unpublished trial; checks run on IPD suggest ade-
quate sequence generation
Allocation concealment (selection bias) Low risk Comment: unpublished, insufficient information provided, but
collection of IPD and correspondence with those who supplied
the data reassured that data were adequate
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: trial not blinded owing to the nature of the inter-
vention; outcome not likely influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: individual participant data obtained and checked for
all outcomes
Selective reporting (reporting bias) Low risk Comment: individual participant data obtained and checked for
all outcomes
Other bias Low risk Comment: study apparently free of other sources of bias
GETCB 04CB86
Methods 1986 to 1994
RCT
Participants 189 patients
Stages I, II, III
Trial data used in subgroup analyses for sex, age, stage and nodal status
Interventions Surgery + radiotherapy vs surgery alone
RT details
60 Gy in 24 to 30 fractions in 6 weeks
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GETCB 04CB86 (Continued)
Prescription technique: isocentre
Machine used: Co60 and linac (majority linac)
Average field size (cm): unavailable
Clinical target volume: bronchial stump, hilum, mediastinum
Technique: spinal cord blocks, oblique fields, lateral fields
Outcomes Survival
Notes Same publication as GETCB 05CB88
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomly assigned by centralised telephone procedure”
Comment: stated as randomised in paper; checks run on IPD
suggest adequate sequence generation
Allocation concealment (selection bias) Low risk Comment: randomisation by central telephone call
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: trial not blinded owing to the nature of the inter-
vention; outcome not likely influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: individual participant data obtained and checked for
all outcomes
Selective reporting (reporting bias) Low risk Comment: individual participant data obtained and checked for
all outcomes
Other bias Low risk Comment: study apparently free of other sources of bias
GETCB 05CB88
Methods 1988 to 1994
RCT
Participants 539 patients
Stages I, II, III
Trial data used in subgroup analyses for sex, age, stage and nodal status
Interventions Surgery + radiotherapy vs surgery alone
RT details
60 Gy in 24 to 30 fractions in 6 weeks
Prescription technique: isocentre
Machine used: Co60 and linac (majority linac)
Average field size (cm): unavailable
Clinical target volume: bronchial stump, hilum, mediastinum
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GETCB 05CB88 (Continued)
Technique: spinal cord blocks, oblique fields, lateral fields
Outcomes Survival
Notes Same publication as GETCB 04CB86
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomly assigned by centralised telephone procedure”
Comment: stated as randomised in paper; checks run on IPD
suggest adequate sequence generation
Allocation concealment (selection bias) Low risk Comment: randomisation by central telephone call
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: trial not blinded owing to the nature of the inter-
vention; outcome not likely influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: individual participant data obtained and checked for
all outcomes
Selective reporting (reporting bias) Low risk Comment: individual participant data obtained and checked for
all outcomes
Other bias Low risk Comment: study apparently free of other sources of bias
Italy 2002
Methods 1989 to 1997
RCT
Participants 104 patients
Stage I
Trial data used in subgroup analyses for age, sex, histology and stage
Interventions Surgery + radiotherapy vs surgery alone
RT details
50.4 Gy in 1.8 Gy/d in 5 weeks and 3 days
Prescription technique: angled field technique machine used: linac
Average field size (cm): unavailable
Clinical target volume: bronchial stump, hilum, mediastinum
Technique: unavailable
Outcomes Survival
Notes -
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Italy 2002 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “by chance” using computer-generated model
Comment: stated as randomised in paper; checks run on IPD
suggest adequate sequence generation
Allocation concealment (selection bias) Low risk Comment: computer-generated randomisation, which was
checked by an independent colleague
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: trial not blinded owing to the nature of the inter-
vention; outcome not likely influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: individual participant data obtained and checked for
all outcomes
Selective reporting (reporting bias) Low risk Comment: individual participant data obtained and checked for
all outcomes
Other bias Low risk Comment: study apparently free of other sources of bias
Korea 2007
Methods 1989 to 1998
RCT
Participants 111 patients
Stages II, III
Trial data used in subgroup analyses for sex, age, histology, stage and nodal status
Interventions Surgery + radiotherapy vs surgery alone
RT details
50.4 to 55.8 Gy in 1.8 to 2 Gy fractions, 5 times a week
Prescription technique: at midplane
Average field size: defined inferiorly by a point 5 cm below the carina and superiorly by
the suprasternal notch
Clinical target volume: tumour bed, bronchial stump, ipsilateral hilum, vascular shadows
of the bilateral mediastinum
Technique: combination of parallel opposed, and anterior and posterior oblique fields,
or any combination chosen at the discretion of the chest radiation oncologist
Outcomes Survival
Notes Abstract only
Risk of bias
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Korea 2007 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: stated as randomised in paper; checks run on IPD
suggest adequate sequence generation
Allocation concealment (selection bias) Low risk Comment: insufficient information provided in abstract, but
collection of IPD and correspondence with those who supplied
the data reassured that data were adequate
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: trial not blinded owing to the nature of the inter-
vention; outcome not likely influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: individual participant data obtained and checked for
all outcomes
Selective reporting (reporting bias) Low risk Comment: individual participant data obtained and checked for
all outcomes
Other bias Low risk Comment: study apparently free of other sources of bias
LCSG 773
Methods 1978 to 1985
RCT
Participants 230 patients
Stages II, III
Trial data used in subgroup analyses for sex, age, histology, stage and nodal status
Interventions Surgery + radiotherapy vs surgery alone
RT details
50 Gy in 25 to 27.5 fractions in 5 to 5.5 weeks
Prescription technique: central axis, at midplane
Machine used: Co60 and linac
Average field size (cm): unavailable
Clinical target volume: bronchial stump, hilum, mediastinum
Technique: spinal cord blocks, oblique fields, lateral fields
Outcomes Survival
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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LCSG 773 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “permuted block randomisation”
Comment: stated as randomised in paper; checks run on IPD
suggest adequate sequence generation
Allocation concealment (selection bias) Low risk Quote: treatment assigned by central office
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: trial not blinded owing to the nature of intervention;
outcome not likely influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: individual participant data obtained and checked for
all outcomes
Selective reporting (reporting bias) Low risk Comment: individual participant data obtained and checked for
all outcomes
Other bias Low risk Comment: study apparently free of other sources of bias
Lille 1985
Methods 1985 to 1991
RCT
Participants 163 patients
Stage I
Trial data used in subgroup analyses for sex, age, histology, stage and nodal status
Interventions Surgery + radiotherapy vs surgery alone
RT details
45 to 60 Gy in 22.5 to 30 fractions in 6 weeks
Prescription technique: isodose 90%
Machine used: Co60 and linac
Average field size (cm): 12 × 12
Clinical target volume: hilum, upper mediastinum
Technique: spinal cord blocks, oblique fields, lateral fields
Outcomes Survival
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomised with a table of randomisation according to
Snedecor and Cochran”
Comment: stated as randomised in paper; checks run on IPD
suggest adequate sequence generation
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Lille 1985 (Continued)
Allocation concealment (selection bias) Low risk Quote: “randomised with a table of randomisation according to
Snedecor and Cochran”; insufficient information provided
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: trial not blinded owing to the nature of the inter-
vention; outcome not likely to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: individual participant data obtained and checked for
all outcomes
Selective reporting (reporting bias) Low risk Comment: individual participant data obtained and checked for
all outcomes
Other bias Low risk Comment: study apparently free of other sources of bias
MRC LU11
Methods 1986 to 1993
RCT
Participants 308 patients
Stages II, III
Trial data used in subgroup analyses for sex, age, histology, stage and nodal status
Interventions Surgery + radiotherapy vs surgery alone
RT details
40 Gy in 15 fractions in 3 weeks
Prescription technique: central axis, at midplane
Machine used: Co60 and linac
Average field size (cm): unavailable
Clinical target volume: hilum, mediastinum, supraclavicular fossae for upper lobes
Technique: spinal cord blocks, oblique fields, lateral fields
Outcomes Survival
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: stated as randomised in paper; checks run on IPD
suggest adequate sequence generation
Allocation concealment (selection bias) Low risk Quote: “treatment assigned by central office”
28Postoperative radiotherapy for non-small cell lung cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
MRC LU11 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: trial not blinded owing to the nature of the inter-
vention; outcome not likely influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: individual participant data obtained and checked for
all outcomes
Selective reporting (reporting bias) Low risk Comment: individual participant data obtained and checked for
all outcomes
Other bias Low risk Comment: study apparently free of other sources of bias
Slovenia 1988
Methods 1988 to 1992 RCT
Participants 74 patients
Stage III
Trial data used in subgroup analyses for sex, age, histology, stage and nodal status
Interventions Surgery + radiotherapy vs surgery alone
RT details
30 Gy in 10 to 12 fractions in 2 weeks
Prescription technique: central axis, at the midplane
Machine used: linac
Average field size (cm): 9 × 12
Clinical target volume: hilum, mediastinum
Technique: oblique fields, lateral fields
Outcomes Survival
Notes Sealed envelope randomisation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: stated as randomised in paper; checks run on IPD
suggest adequate sequence generation
Allocation concealment (selection bias) Low risk Quote: “randomisation carried out via sealed envelope”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: trial not blinded owing to the nature of the inter-
vention; outcome not likely influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: individual participant data obtained and checked for
all outcomes
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Slovenia 1988 (Continued)
Selective reporting (reporting bias) Low risk Comment: individual participant data obtained and checked for
all outcomes
Other bias Low risk Comment: study apparently free of other sources of bias
All trials supplied individual participant data for analysis and therefore are defined as unpublished data, even thoughmost are published.
IPD = individual participant data.
RCT = randomised controlled trial.
RT = radiotherapy.1G
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Austria 1996 Data unavailable/eligibility uncertain
Reported to be an RCT. Data provided by trialists, but anomalies evident between reported results and data received,
and it was not clear if the trial was randomised. We were unable to resolve these problems with the trialists
Dymek 2003 Eligible
Data could not be obtained
LCSG 841 Eligible
Data could not be obtained (5 participants)
RCT = randomised controlled trial.
Characteristics of ongoing studies [ordered by study ID]
Lung ART-IGR 2006/1202
Trial name or title Essai de phase III comparant une radiothérapie médiastinale conformationnelle post-opératoire à l’absence de
radiothérapie après chirurgie complète chez des patients présentant un carcinome bronchique non à petites
cellules (CBNPC) avec envahissement médiastinal N2
Methods Phase III multi-centric
Participants
Interventions
Outcomes Evaluation de l’impact de la radiothérapie médiastinale conformationnelle sur la survie sans récidive comparé
à l’absence de radiothérapie
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Lung ART-IGR 2006/1202 (Continued)
Starting date 2006
Contact information Docteur Cécile Le Péchoux - lepechoux@igr.fr
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Surgery + PORT versus surgery alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Survival 11 2343 Hazard Ratio (95% CI) 1.18 [1.07, 1.31]
2 Local recurrence-free survival 11 2343 Hazard Ratio (95% CI) 1.12 [1.01, 1.23]
3 Distant recurrence-free survival 11 2343 Hazard Ratio (95% CI) 1.13 [1.02, 1.24]
4 Recurrence-free survival 11 2343 Hazard Ratio (95% CI) 1.10 [0.99, 1.21]
5 RT delivery method 11 2343 Hazard Ratio (95% CI) 1.18 [1.07, 1.31]
5.1 Cobalt-60 only 1 202 Hazard Ratio (95% CI) 1.48 [1.09, 2.02]
5.2 Cobalt-60 and linac 6 1746 Hazard Ratio (95% CI) 1.18 [1.05, 1.33]
5.3 Linac only 4 395 Hazard Ratio (95% CI) 1.02 [0.80, 1.31]
6 RT dose 11 2343 Peto Odds Ratio (95% CI) 1.18 [1.07, 1.31]
6.1 < 45 Gy 2 382 Peto Odds Ratio (95% CI) 0.93 [0.75, 1.17]
6.2 ≥ 45 Gy 9 1961 Peto Odds Ratio (95% CI) 1.25 [1.12, 1.40]
Analysis 1.1. Comparison 1 Surgery + PORT versus surgery alone, Outcome 1 Survival.
Review: Postoperative radiotherapy for non-small cell lung cancer
Comparison: 1 Surgery + PORT versus surgery alone
Outcome: 1 Survival
Study or subgroup Surgery + PORT Surgery Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Belgium 1966 88/98 80/104 10.9 % 1.48 [ 1.09, 2.02 ]
LCSG 773 84/110 81/120 11.0 % 1.12 [ 0.83, 1.53 ]
CAMS 1981 83/153 100/164 12.0 % 1.02 [ 0.76, 1.37 ]
Lille 1985 59/81 45/82 6.9 % 1.53 [ 1.04, 2.25 ]
EORTC 08861 26/52 20/54 3.0 % 1.64 [ 0.91, 2.94 ]
MRC LU11 116/154 123/154 15.9 % 0.96 [ 0.74, 1.24 ]
GETCB 04CB86 69/99 59/90 8.5 % 1.17 [ 0.83, 1.66 ]
Slovenia 1988 30/35 33/39 4.2 % 0.85 [ 0.52, 1.39 ]
GETCB 05CB88 152/274 120/265 18.0 % 1.45 [ 1.14, 1.85 ]
0.1 0.2 0.5 1 2 5 10
Favours PORT Favours no PORT
(Continued . . . )
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(. . . Continued)
Study or subgroup Surgery + PORT Surgery Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Italy 2002 23/51 30/53 3.5 % 0.71 [ 0.41, 1.22 ]
Korea 2007 47/56 43/55 6.0 % 1.15 [ 0.76, 1.73 ]
Total (95% CI) 100.0 % 1.18 [ 1.07, 1.31 ]
Heterogeneity: Chi2 = 16.65, df = 10 (P = 0.08); I2 =40%
Test for overall effect: Z = 3.20 (P = 0.0014)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours PORT Favours no PORT
Analysis 1.2. Comparison 1 Surgery + PORT versus surgery alone, Outcome 2 Local recurrence-free
survival.
Review: Postoperative radiotherapy for non-small cell lung cancer
Comparison: 1 Surgery + PORT versus surgery alone
Outcome: 2 Local recurrence-free survival
Study or subgroup Surgery + PORT Surgery Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Belgium 1966 88/98 80/104 10.6 % 1.44 [ 1.06, 1.96 ]
LCSG 773 85/110 81/120 10.7 % 1.09 [ 0.80, 1.48 ]
CAMS 1981 91/153 111/164 13.0 % 0.94 [ 0.71, 1.24 ]
Lille 1985 59/81 45/82 6.7 % 1.50 [ 1.02, 2.21 ]
EORTC 08861 26/52 23/54 3.1 % 1.29 [ 0.73, 2.26 ]
MRC LU11 118/154 125/154 15.7 % 0.97 [ 0.75, 1.25 ]
GETCB 04CB86 70/99 61/90 8.4 % 1.04 [ 0.74, 1.47 ]
Slovenia 1988 30/35 33/39 4.1 % 0.94 [ 0.58, 1.55 ]
GETCB 05CB88 156/274 127/265 18.2 % 1.39 [ 1.10, 1.75 ]
Italy 2002 23/51 34/53 3.7 % 0.55 [ 0.33, 0.93 ]
0.1 0.2 0.5 1 2 5 10
Favours PORT Favours no PORT
(Continued . . . )
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(. . . Continued)
Study or subgroup Surgery + PORT Surgery Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Korea 2007 47/56 43/55 5.8 % 1.05 [ 0.69, 1.58 ]
Total (95% CI) 100.0 % 1.12 [ 1.01, 1.23 ]
Heterogeneity: Chi2 = 18.86, df = 10 (P = 0.04); I2 =47%
Test for overall effect: Z = 2.18 (P = 0.029)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours PORT Favours no PORT
Analysis 1.3. Comparison 1 Surgery + PORT versus surgery alone, Outcome 3 Distant recurrence-free
survival.
Review: Postoperative radiotherapy for non-small cell lung cancer
Comparison: 1 Surgery + PORT versus surgery alone
Outcome: 3 Distant recurrence-free survival
Study or subgroup Surgery + PORT Surgery Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Belgium 1966 88/98 80/104 10.5 % 1.50 [ 1.10, 2.04 ]
LCSG 773 86/110 84/120 10.9 % 1.09 [ 0.81, 1.48 ]
CAMS 1981 89/153 108/164 12.5 % 0.97 [ 0.73, 1.28 ]
Lille 1985 60/81 45/82 6.7 % 1.52 [ 1.03, 2.23 ]
EORTC 08861 28/52 23/54 3.2 % 1.50 [ 0.86, 2.62 ]
MRC LU11 118/154 124/154 15.5 % 0.95 [ 0.73, 1.22 ]
GETCB 04CB86 71/99 61/90 8.4 % 1.09 [ 0.77, 1.53 ]
Slovenia 1988 30/35 33/39 4.0 % 0.87 [ 0.53, 1.43 ]
GETCB 05CB88 158/274 138/265 18.9 % 1.27 [ 1.01, 1.60 ]
Italy 2002 23/51 31/53 3.5 % 0.72 [ 0.42, 1.23 ]
Korea 2007 48/56 44/55 5.9 % 1.07 [ 0.71, 1.61 ]
0.1 0.2 0.5 1 2 5 10
Favours PORT Favours no PORT
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(. . . Continued)
Study or subgroup Surgery + PORT Surgery Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Total (95% CI) 100.0 % 1.13 [ 1.02, 1.24 ]
Heterogeneity: Chi2 = 14.51, df = 10 (P = 0.15); I2 =31%
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours PORT Favours no PORT
Analysis 1.4. Comparison 1 Surgery + PORT versus surgery alone, Outcome 4 Recurrence-free survival.
Review: Postoperative radiotherapy for non-small cell lung cancer
Comparison: 1 Surgery + PORT versus surgery alone
Outcome: 4 Recurrence-free survival
Study or subgroup Surgery + PORT Surgery Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Belgium 1966 88/98 80/104 10.3 % 1.46 [ 1.07, 1.98 ]
LCSG 773 87/110 84/120 10.8 % 1.06 [ 0.78, 1.43 ]
CAMS 1981 93/153 115/164 13.0 % 0.91 [ 0.69, 1.20 ]
Lille 1985 60/81 45/82 6.6 % 1.49 [ 1.01, 2.19 ]
EORTC 08861 28/52 23/54 3.2 % 1.44 [ 0.82, 2.50 ]
MRC LU11 120/154 125/154 15.4 % 0.97 [ 0.76, 1.25 ]
GETCB 04CB86 72/99 62/90 8.4 % 1.05 [ 0.75, 1.47 ]
Slovenia 1988 30/35 33/39 4.0 % 0.97 [ 0.59, 1.58 ]
GETCB 05CB88 161/274 141/265 18.9 % 1.27 [ 1.01, 1.59 ]
Italy 2002 23/51 35/53 3.6 % 0.56 [ 0.34, 0.95 ]
Korea 2007 48/56 44/55 5.8 % 1.00 [ 0.66, 1.51 ]
Total (95% CI) 100.0 % 1.10 [ 0.99, 1.21 ]
Heterogeneity: Chi2 = 17.79, df = 10 (P = 0.06); I2 =44%
Test for overall effect: Z = 1.84 (P = 0.065)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours PORT Favours no PORT
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Analysis 1.5. Comparison 1 Surgery + PORT versus surgery alone, Outcome 5 RT delivery method.
Review: Postoperative radiotherapy for non-small cell lung cancer
Comparison: 1 Surgery + PORT versus surgery alone
Outcome: 5 RT delivery method
Study or subgroup Surgery + PORT Surgery Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 Cobalt-60 only
Belgium 1966 88/98 80/104 10.9 % 1.48 [ 1.09, 2.02 ]
Subtotal (95% CI) 98 104 10.9 % 1.48 [ 1.09, 2.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.012)
2 Cobalt-60 and linac
CAMS 1981 83/153 100/164 12.0 % 1.02 [ 0.76, 1.37 ]
GETCB 04CB86 69/99 59/90 8.5 % 1.17 [ 0.83, 1.66 ]
GETCB 05CB88 152/274 120/265 18.0 % 1.45 [ 1.14, 1.85 ]
LCSG 773 84/110 81/120 11.0 % 1.12 [ 0.83, 1.53 ]
Lille 1985 59/81 45/82 6.9 % 1.53 [ 1.04, 2.25 ]
MRC LU11 116/154 123/154 15.9 % 0.96 [ 0.74, 1.24 ]
Subtotal (95% CI) 871 875 72.3 % 1.18 [ 1.05, 1.33 ]
Heterogeneity: Chi2 = 8.20, df = 5 (P = 0.15); I2 =39%
Test for overall effect: Z = 2.70 (P = 0.0070)
3 Linac only
EORTC 08861 26/52 20/54 3.0 % 1.64 [ 0.91, 2.94 ]
Italy 2002 23/51 30/53 3.5 % 0.71 [ 0.41, 1.22 ]
Korea 2007 47/56 43/55 6.0 % 1.15 [ 0.76, 1.73 ]
Slovenia 1988 30/35 33/39 4.2 % 0.85 [ 0.52, 1.39 ]
Subtotal (95% CI) 194 201 16.8 % 1.02 [ 0.80, 1.31 ]
Heterogeneity: Chi2 = 5.08, df = 3 (P = 0.17); I2 =41%
Test for overall effect: Z = 0.19 (P = 0.85)
Total (95% CI) 100.0 % 1.18 [ 1.07, 1.31 ]
0.2 0.5 1 2 5
Favours experimental Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup Surgery + PORT Surgery Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Heterogeneity: Chi2 = 16.65, df = 10 (P = 0.08); I2 =40%
Test for overall effect: Z = 3.20 (P = 0.0014)
Test for subgroup differences: Chi2 = 3.38, df = 2 (P = 0.18), I2 =41%
0.2 0.5 1 2 5
Favours experimental Favours control
Analysis 1.6. Comparison 1 Surgery + PORT versus surgery alone, Outcome 6 RT dose.
Review: Postoperative radiotherapy for non-small cell lung cancer
Comparison: 1 Surgery + PORT versus surgery alone
Outcome: 6 RT dose
Study or subgroup Surgery + PORT Surgery
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 < 45 Gy
MRC LU11 116/154 123/154 15.9 % 0.96 [ 0.74, 1.24 ]
Slovenia 1988 30/35 33/39 4.2 % 0.85 [ 0.52, 1.39 ]
Subtotal (95% CI) 189 193 20.1 % 0.93 [ 0.75, 1.17 ]
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
2 ≥ 45 Gy
Belgium 1966 88/98 80/104 10.9 % 1.48 [ 1.09, 2.02 ]
CAMS 1981 83/153 100/164 12.0 % 1.02 [ 0.76, 1.37 ]
EORTC 08861 26/52 20/54 3.0 % 1.64 [ 0.91, 2.94 ]
GETCB 04CB86 69/99 59/90 8.5 % 1.17 [ 0.83, 1.66 ]
GETCB 05CB88 152/274 120/265 18.0 % 1.45 [ 1.14, 1.85 ]
Italy 2002 23/51 30/53 3.5 % 0.71 [ 0.41, 1.22 ]
Korea 2007 47/56 43/55 6.0 % 1.15 [ 0.76, 1.73 ]
0.01 0.1 1 10 100
Favours experimental Favours control
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(. . . Continued)
Study or subgroup Surgery + PORT Surgery
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
LCSG 773 84/110 81/120 11.0 % 1.12 [ 0.83, 1.53 ]
Lille 1985 59/81 45/82 6.9 % 1.53 [ 1.04, 2.25 ]
Subtotal (95% CI) 974 987 79.9 % 1.25 [ 1.12, 1.40 ]
Heterogeneity: Chi2 = 11.34, df = 8 (P = 0.18); I2 =29%
Test for overall effect: Z = 3.88 (P = 0.00011)
Total (95% CI) 100.0 % 1.18 [ 1.07, 1.31 ]
Heterogeneity: Chi2 = 16.65, df = 10 (P = 0.08); I2 =40%
Test for overall effect: Z = 3.20 (P = 0.0014)
Test for subgroup differences: Chi2 = 5.12, df = 1 (P = 0.02), I2 =80%
0.01 0.1 1 10 100
Favours experimental Favours control
A D D I T I O N A L T A B L E S
Table 1. Common meta-analysis stage scale (original analyses - based on TNM 4th edition)
T stage N stage M stage Meta-analysis stage AJCC stage
0, 1, 2, X, iS 0 0 I I
0, 1, 2, X, iS 1 0 II II
Any 2, 3 0 III III non-metastatic
3, 4 Any 0 III III non-metastatic
Any Any 1 IV Any metastatic
AJCC = American Joint Committee on Cancer.
Table 2. Common meta-analysis stage scale (current analysis - based on TNM 6th edition)
T stage N stage M stage Meta-analysis stage
1, 2 0 0 I
1, 2 1 0 II
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Table 2. Common meta-analysis stage scale (current analysis - based on TNM 6th edition) (Continued)
3 0 0 II
1, 2 2 0 III
3 1, 2 0 III
Any Any 1 IV
Table 3. Characteristics of participants in PORT meta-analysis
Characteristic Postoperative RT Surgery only Total
AGE (data from 11 trials)
< 54 years 294 327 621
55 to 59 years 267 261 528
60 to 64 years 290 276 566
> 65 years 312 315 627
Unknown 0 1 1
SEX (data from 11 trials)
Male 988 992 1980
Female 175 187 362
Not recorded 0 1 1
HISTOLOGY (data from 9 trials)
Adenocarcinoma 195 218 413
Squamous 522 545 1067
Other 66 54 120
Unknown 380 363 743
META-ANALYSIS STAGE (data from 11 trials)
I 328 338 666
II 353 366 719
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Table 3. Characteristics of participants in PORT meta-analysis (Continued)
III 463 455 918
IV 1 0 1
Unknown 18 21 39
WHO PERFORMANCE STATUS (data from 4 trials; not used)
Good (0, 1) 195 196 391
Poor (2, 3, 4) 77 83 160
Unknown 22 21 43
Table 4. Changes in results over time
Trend or interaction
1998
Trend or interaction
2005
Trend or interaction
2010 ’old’ methods
Trend or interaction
2010 ’new’ methods
and TNM changes
Age P = 0.34 P = 0.44 P = 0.32 P = 0.20
Sex P = 0.94 P = 0.92 P = 0.84 P = 0.49
Histology P = 0.75 P = 0.61 P = 0.42 P = 0.38
Stage P = 0.0003 P = 0.003 P = 0.003 P = 0.12
Nodal status P = 0.016 P = 0.02 P = 0.03 P = 0.39
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy (via PubMed)
#1 Search Carcinoma, Non-Small-Cell Lung[MeSH Terms]
#2 Search nsclc[Title/Abstract]
#3 Search lung cancer*[Title/Abstract]
#4 Search lung carcinoma[Title/Abstract]
#5 Search lung neoplasm*[Title/Abstract]
#6 Search lung tumor*[Title/Abstract]
#7 Search lung tumour*[Title/Abstract]
#8 Search non-small cell*[Title/Abstract]
#9 Search nonsmall cell*[Title/Abstract]
#10 Search (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7) AND (#8 OR #9)
#11 Search Thoracic surgery[MeSH Terms]
#12 Search surg*[Title/Abstract]
#13 Search thoracic surgical procedures[MeSH Terms]
#14 Search pneumonectomy[MeSH Terms]
#15 Search pneumonectom*[Title/Abstract]
#16 Search lobectom*[Title/Abstract]
#17 Search Lung/surgery[MeSH Terms]
#18 Search thoracotomy[MeSH Terms]
#19 Search Thoracotom*[Title/Abstract]
#20 Search Radiotherapy[MeSH Terms]
#21 Search Radiother*[Title/Abstract]
#22 Search PORT[Title/Abstract]
#23 Search radiation therap*[Title/Abstract]
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(Continued)
#24 Search (#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19) AND (#20 OR #21 OR #22 OR #23)
#25 Search #10 AND #24
#26 Search randomized controlled trial[Publication Type]
#27 Search controlled clinical trial[Publication Type]
#28 Search randomized[Title/Abstract]
#29 Search placebo[Title/Abstract]
#30 Search drug therapy[MeSH Terms]
#31 Search randomly[Title/Abstract]
#32 Search trial[Title/Abstract]
#33 Search groups[Title/Abstract]
#34 Search (#25 OR #26 OR #27 OR #28 OR #29 OR #30OR #31 OR #32 OR #33)
#35 Search animals[MeSH Terms]
#36 Search humans[MeSH Terms]
#37 Search #35 NOT #36
#38 Search #34 NOT #37
#39 Search #25 AND #38
Appendix 2. CENTRAL search strategy
#1 lung cancer*
#2 non-small cell*
#3 non small cell*
#4 nonsmall cell*
#5 MeSH descriptor: [Lung Neoplasms] explode all trees
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(Continued)
#6 MeSH descriptor: [Carcinoma, Non-Small-Cell Lung] explode all trees
#7 Nsclc
#8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
#9 MeSH descriptor: [Thoracic Surgery] explode all trees
#10 surg*
#11 MeSH descriptor: [Thoracic Surgical Procedures] explode all trees
#12 MeSH descriptor: [Pneumonectomy] explode all trees
#13 pneumonectom*
#14 lobectom*
#15 MeSH descriptor: [Lung] explode all trees and with qualifier(s): [Surgery - SU]
#16 MeSH descriptor: [Thoracotomy] explode all trees
#17 thoracotom*
#18 MeSH descriptor: [Radiotherapy] explode all trees
#19 Radiotherap*
#20 radiation therap*
#21 PORT
#22 (#9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17) and (#18 or #19 or #20 or #21)
WH A T ’ S N E W
Last assessed as up-to-date: 8 July 2016.
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Date Event Description
18 July 2016 New citation required but conclusions have not changed Changes in authorship
18 July 2016 New search has been performed Full update, no new studies - conclusions not changed,
some changes to subgroup conclusions as newer, more
appropriate methods have been used
H I S T O R Y
Protocol first published: Issue 2, 2000
Review first published: Issue 1, 2000
Date Event Description
5 November 2009 Amended New PLS added
12 May 2009 Amended Name of group author slightly changed
19 January 2009 New search has been performed Full update, new trial data included
22 May 2008 Amended Converted to new review format
25 October 2004 New citation required and conclusions have changed Substantive amendments made
C O N T R I B U T I O N S O F A U T H O R S
The writing group for the current version of this review consisted of S Burdett, LHM Rydzewska, JF Tierney, MKB Parmar, D Fisher,
R Arriagada, JP Pignon and C Le Pechoux, on behalf of the PORT Meta-analysis Trialists Group.
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D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Medical Research Council, UK.
External sources
• NHS R&D programme project grant NCP/U03, UK.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Carcinoma, Non-Small-Cell Lung [∗radiotherapy; surgery]; Lung Neoplasms [∗radiotherapy; surgery]; Radiotherapy, Adjuvant; Ran-
domized Controlled Trials as Topic
MeSH check words
Humans
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